Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Rimini, M; Rimassa, L; Ueshima, K; Burgio, V; Shigeo, S; Tada, T; Suda, G; Yoo, C; Cheon, J; Pinato, DJ; Lonardi, S; Scartozzi, M; Iavarone, M; Di Costanzo, GG; Marra, F; Solda, C; Tamburini, E; Piscaglia, F; Masi, G; Cabibbo, G; Foschi, FG; Silletta, M; Pressiani, T; Nishida, N; Iwamoto, H; Sakamoto, N; Ryoo, BY; Chon, HJ; Claudia, F; Niizeki, T; Sho, T; Kang, B; D'Alessio, A; Kumada, T; Hiraoka, A; Hirooka, M; Kariyama, K; Tani, J; Atsukawa, M; Takaguchi, K; Itobayashi, E; Fukunishi, S; Tsuji, K; Ishikawa, T; Tajiri, K; Ochi, H; Yasuda, S; Toyoda, H; Ogawa, C; Nishimur, T; Hatanaka, T; Kakizaki, S; Shimada, N; Kawata, K; Tanaka, T; Ohama, H; Nouso, K; Morishita, A; Tsutsui, A; Nagano, T; Itokawa, N; Okubo, T; Arai, T; Imai, M; Naganuma, A; Koizumi, Y; Nakamura, S; Joko, K; Iijima, H; Hiasa, Y; Pedica, F; De Cobelli, F; Ratti, F; Alrighetti, L; Kudo, M; Cascinu, S; Casadei-Gardini, A

Casadei-Gardini, A (通讯作者),IRCCS San Raffaele Hosp, Dept Med Oncol, Via Olgettina 60, Milan, Italy.

ESMO OPEN, 2022; 7 (6):

Abstract

Background: A growing body of evidence suggests that non-viral hepatocellular carcinoma (HCC) might benefit less from immunotherapy. Materials and met......

Full Text Link